Emergent BioSolutions Inc.EBSEarnings & Financial Report
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
EBS Q4 FY2025 Key Financial Metrics
Revenue
$148.7M
Gross Profit
$63.8M
Operating Profit
$-27.9M
Net Profit
$-54.6M
Gross Margin
42.9%
Operating Margin
-18.8%
Net Margin
-36.7%
YoY Growth
-23.6%
EPS
$-0.95
Emergent BioSolutions Inc. Q4 FY2025 Financial Summary
Emergent BioSolutions Inc. reported revenue of $148.7M (down 23.6% YoY) for Q4 FY2025, with a net profit of $-54.6M (down 74.4% YoY) (-36.7% margin). Cost of goods sold was $84.9M, operating expenses totaled $91.7M.
Key Financial Metrics
| Total Revenue | $148.7M |
|---|---|
| Net Profit | $-54.6M |
| Gross Margin | 42.9% |
| Operating Margin | -18.8% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Emergent BioSolutions Inc. Q4 FY2025 revenue of $148.7M breaks down across 3 segments, led by Medical Countermeasures MCM Product at $99.2M (66.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Medical Countermeasures MCM Product | $99.2M | 66.7% |
| Commercial Products Segment | $38.4M | 25.8% |
| All Other Revenue | $11.1M | 7.5% |
Emergent BioSolutions Inc. Revenue by Segment — Quarterly Trend
Emergent BioSolutions Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Medical Countermeasures MCM Product and Commercial Products Segment) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Medical Countermeasures MCM Product | $99.2M | $142.5M | $58.4M | $156.6M |
| Commercial Products Segment | $38.4M | $74.9M | $67.5M | $45.3M |
| All Other Revenue | $11.1M | $13.7M | $15.0M | $20.3M |
Emergent BioSolutions Inc. Annual Revenue by Year
Emergent BioSolutions Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $742.9M).
Emergent BioSolutions Inc. Quarterly Revenue & Net Profit History
Emergent BioSolutions Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $148.7M | -23.6% | $-54.6M | -36.7% |
| Q3 FY2025 | $231.1M | -21.3% | $51.2M | 22.2% |
| Q2 FY2025 | $140.9M | -44.7% | $-12.0M | -8.5% |
| Q1 FY2025 | $222.2M | -26.0% | $68.0M | 30.6% |
| Q4 FY2024 | $194.7M | -29.6% | $-31.3M | -16.1% |
| Q3 FY2024 | $293.8M | +8.6% | $114.8M | 39.1% |
| Q2 FY2024 | $254.7M | -24.6% | $-283.1M | -111.2% |
| Q1 FY2024 | $300.4M | +82.8% | $9.0M | 3.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $300.4M | $254.7M | $293.8M | $194.7M | $222.2M | $140.9M | $231.1M | $148.7M |
| YoY Growth | 82.8% | -24.6% | 8.6% | -29.6% | -26.0% | -44.7% | -21.3% | -23.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.80B | $1.51B | $1.48B | $1.39B | $1.43B | $1.42B | $1.46B | $1.32B |
| Liabilities | $1.14B | $1.13B | $969.4M | $906.9M | $873.4M | $880.9M | $878.5M | $796.0M |
| Equity | $663.9M | $386.3M | $508.4M | $482.8M | $552.7M | $536.2M | $582.5M | $522.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-62.6M | $47.5M | $153.7M | $-79.9M | $-11.2M | $106.4M | $-2.3M | $77.7M |